Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase I Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Summary

The purpose of this phase I study is to determine the maximum tolerated dose (MTD) for CDX-1140 and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.

General Information

NCT#: NCT03329950
Study ID: CDX1140-01
Trial Phase: Phase I

Trial Sponsor: Celldex Therapeutics
Therapies Used in This Trial: CDX-1140, CDX-301

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search